COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA

Cognitive functioning is moderately to severely impaired in patients with schizophrenia. This impairment is the prime driver of the significant disabilities in occupational, social, and economic functioning in patients with schizophrenia and an important treatment target. The profile of deficits in schizophrenia includes many of the most important aspects of human cognition: attention, memory, reasoning, and processing speed. While various efforts are under way to identify specific aspects of neurocognition that may lie closest to the neurobiological etiology and pathophysiology of the illness, and may provide relevant convergence with animal models of cognition, standard neuropsychological measures continue to demonstrate the greatest sensitivity to functionally relevant cognitive impairment.The effects of antipsychotic medications on cognition in schizophrenia and first-episode psychosis appear to be minimal. Important work on the effects of add-on pharmacologic treatments is ongoing. Very few of the studies completed to date have had sufficient statistical power to generate firm conclusions; recent studies examining novel add-on treatments have produced some encouraging findings. Cognitive remediation programs have generated considerable interest as these methods are far less costly than pharmacologic treatment and are likely to be safer. A growing consensus suggests that these interventions produce modest gains for patients with schizophrenia, but the efficacy of the various methods used has not been empirically investigated.

[1]  H. Kraemer,et al.  Evaluation of comparative treatment trials: assessing clinical benefits and risks for patients, rather than statistical effects on measures. , 2010, JAMA.

[2]  Richie Poulton,et al.  Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. , 2010, The American journal of psychiatry.

[3]  Larry J. Seidman,et al.  NEUROPSYCHOLOGY OF THE PRODROME TO PSYCHOSIS IN THE NAPLS CONSORTIUM: RELATIONSHIP TO FAMILY HISTORY AND CONVERSION TO PSYCHOSIS , 2008, Schizophrenia Research.

[4]  R. Hamer,et al.  Feasibility and Pilot Efficacy Results from the Multi-site Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Study , 2010 .

[5]  D. Barch,et al.  Anticipating DSM-V: opportunities and challenges for cognition and psychosis. , 2010, Schizophrenia bulletin.

[6]  Philip D. Harvey,et al.  Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. , 2009, Schizophrenia bulletin.

[7]  R. Keefe,et al.  Memory-Prediction Errors and Their Consequences in Schizophrenia , 2009, Neuropsychology Review.

[8]  R. Keefe,et al.  Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. , 2009, Annals of the Academy of Medicine, Singapore.

[9]  J. Lieberman,et al.  Relationship of cognition and psychopathology to functional impairment in schizophrenia. , 2008, The American journal of psychiatry.

[10]  Michael F. Green,et al.  Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative , 2008, Biological Psychiatry.

[11]  Herbert Y Meltzer,et al.  Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Neuropsychopharmacology.

[12]  Philip D. Harvey,et al.  Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study , 2008, Journal of the International Neuropsychological Society.

[13]  Philip D. Harvey,et al.  Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. , 2008, Journal of psychiatric research.

[14]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. , 2008, The American journal of psychiatry.

[15]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. , 2008, The American journal of psychiatry.

[16]  Philip D. Harvey,et al.  Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. , 2007, Schizophrenia bulletin.

[17]  Tyrone D. Cannon,et al.  Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. , 2008, Archives of general psychiatry.

[18]  E. Twamley,et al.  A meta-analysis of cognitive remediation in schizophrenia. , 2007, The American journal of psychiatry.

[19]  Michael F. Green,et al.  How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. , 2007, Schizophrenia bulletin.

[20]  Philip D. Harvey,et al.  Performance-based measures of functional skills: usefulness in clinical treatment studies. , 2007, Schizophrenia bulletin.

[21]  C. Carter,et al.  Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. , 2007, Schizophrenia bulletin.

[22]  W. Fenton,et al.  How should DSM-V criteria for schizophrenia include cognitive impairment? , 2007, Schizophrenia bulletin.

[23]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[24]  J. Gold,et al.  Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. , 2007, Archives of general psychiatry.

[25]  S. McGurk,et al.  Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. , 2007, The American journal of psychiatry.

[26]  Philip D. Harvey,et al.  Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: Evidence for specificity of relationships? , 2007, Schizophrenia Research.

[27]  Diana O. Perkins,et al.  A longitudinal study of neurocognitive function in individuals at-risk for psychosis , 2006, Schizophrenia Research.

[28]  J. Sweeney,et al.  Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. , 2006, Archives of general psychiatry.

[29]  Michael F. Green,et al.  Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial , 2006, Neuropsychopharmacology.

[30]  J. Lieberman,et al.  Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic , 2006 .

[31]  Philip D. Harvey,et al.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. , 2005, The American journal of psychiatry.

[32]  M. Chee,et al.  fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. , 2005, The American journal of psychiatry.

[33]  Margaret P. Poe,et al.  Defining a cognitive function decrement in schizophrenia , 2005, Biological Psychiatry.

[34]  Michael F. Green,et al.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.

[35]  W. Gaebel,et al.  Facial expression and emotional face recognition in schizophrenia and depression , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[36]  C. Pantelis,et al.  Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. , 2005, The American journal of psychiatry.

[37]  Michael F. Green,et al.  Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.

[38]  J. Callicott,et al.  Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. , 2004, The American journal of psychiatry.

[39]  Michael F. Green,et al.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria , 2004, Biological Psychiatry.

[40]  R. Gibbs,et al.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Lieberman,et al.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.

[42]  T. McGlashan,et al.  Neuropsychological status of subjects at high risk for a first episode of psychosis , 2004, Schizophrenia Research.

[43]  Michael F. Green,et al.  Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. , 2004, The Journal of clinical psychiatry.

[44]  Steven G Potkin,et al.  Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia , 2004, Schizophrenia Research.

[45]  M. Davidson,et al.  Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode , 2003, Schizophrenia Research.

[46]  C. Pantelis,et al.  Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. , 2003, The American journal of psychiatry.

[47]  R. Gur,et al.  Working memory deficit as a core neuropsychological dysfunction in schizophrenia. , 2003, The American journal of psychiatry.

[48]  Christian R. Dolder,et al.  Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia , 2003, Schizophrenia Research.

[49]  S. McGurk,et al.  Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. , 2003, Psychiatric services.

[50]  S. Potkin,et al.  Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. , 2003, The Journal of clinical psychiatry.

[51]  Jane S. Paulsen,et al.  The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients , 2003, Biological Psychiatry.

[52]  Michael F. Green,et al.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study , 2003, Psychopharmacology.

[53]  Steven J Luck,et al.  Working memory for visual features and conjunctions in schizophrenia. , 2003, Journal of abnormal psychology.

[54]  S. Hyman,et al.  What Are the Right Targets for Psychopharmacology? , 2003, Science.

[55]  Lisa M LaVange,et al.  Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. , 2003, Schizophrenia bulletin.

[56]  S. Hyman,et al.  Medicine. What are the right targets for psychopharmacology? , 2003, Science.

[57]  T. Stroup,et al.  Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (catie) Schizophrenia Trial Send Reprint Requests to Clinical Outcome Measures: Primary Outcome Clinical and Functional Outcomes Table 1. Catie Schizophrenia Trial Centers' Clinical and Func , 2022 .

[58]  R. Rosenheck,et al.  Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. , 2003, Schizophrenia bulletin.

[59]  T. Patterson,et al.  Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. , 2002, The American journal of psychiatry.

[60]  M. Munetz Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia , 2002 .

[61]  J. McEvoy,et al.  Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources , 2002, Schizophrenia Research.

[62]  A. Malla,et al.  Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis , 2002, Psychological Medicine.

[63]  L. Dixon,et al.  Cognitive correlates of job tenure among patients with severe mental illness. , 2002, The American journal of psychiatry.

[64]  Beng-Choon Ho,et al.  Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. , 2002, The American journal of psychiatry.

[65]  L. Friedman Psychoanalysis: Practice and Technique , 2002, Journal of the American Psychoanalytic Association.

[66]  Brian Sheitman,et al.  Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. , 2002, The American journal of psychiatry.

[67]  A. Ertugrul,et al.  The influence of neurocognitive deficits and symptoms on disability in schizophrenia , 2002, Acta psychiatrica Scandinavica.

[68]  Philip D. Harvey,et al.  A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia , 2002, Biological Psychiatry.

[69]  T. Patterson,et al.  Medication Management Ability Assessment: Results From a Performance-Based Measure in Older Outpatients With Schizophrenia , 2002, Journal of clinical psychopharmacology.

[70]  T. Burke,et al.  Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis , 2001, European Psychiatry.

[71]  P. Pattison,et al.  Facial affect and affective prosody recognition in first-episode schizophrenia , 2001, Schizophrenia Research.

[72]  Philip D. Harvey,et al.  Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. , 2001, The American journal of psychiatry.

[73]  M. Green,et al.  Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. , 2001, Schizophrenia bulletin.

[74]  T L Patterson,et al.  UCSD Performance-Based Skills Assessment , 2016 .

[75]  M. Bell,et al.  Work rehabilitation in schizophrenia: does cognitive impairment limit improvement? , 2001, Schizophrenia bulletin.

[76]  D. Ziedonis,et al.  Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. , 2000, The American journal of psychiatry.

[77]  R. Coppola,et al.  Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. , 2000, Cerebral cortex.

[78]  Herbert Y Meltzer,et al.  The role of cognition in vocational functioning in schizophrenia , 2000, Schizophrenia Research.

[79]  Alexander L. Miller,et al.  Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? , 2000, The Journal of nervous and mental disease.

[80]  Jean Addington,et al.  Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study , 2000, Schizophrenia Research.

[81]  B H Mulsant,et al.  Pharmacologic profile of perphenazine's metabolites. , 2000, Journal of clinical psychopharmacology.

[82]  A Labelle,et al.  Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. , 2000, Archives of general psychiatry.

[83]  The paradox of normal neuropsychological function in schizophrenia. , 2000, Journal of abnormal psychology.

[84]  D. Braff,et al.  Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? , 2000, Schizophrenia bulletin.

[85]  R. Kahn,et al.  Memory impairment in schizophrenia: a meta-analysis. , 1999, The American journal of psychiatry.

[86]  A Reichenberg,et al.  Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. , 1999, The American journal of psychiatry.

[87]  Jane S. Paulsen,et al.  Generalized cognitive deficits in schizophrenia: a study of first-episode patients. , 1999, Archives of general psychiatry.

[88]  Norman Ringel,et al.  Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up 1 This work was presented in part at the Winter Workshop on Schizophrenia, Davos, Switzerland, 7–13 February 1998. 1 , 1999, Schizophrenia Research.

[89]  Kathleen S. Jarboe,et al.  The Relationship Between Medication Noncompliance and Cognitive Function in Patients With Schizophrenia , 1999 .

[90]  R. Coppola,et al.  Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. , 1999, Cerebral cortex.

[91]  B. Everitt,et al.  The effects of neurocognitive remediation on executive processing in patients with schizophrenia. , 1999, Schizophrenia bulletin.

[92]  M. Birchwood,et al.  ‘Theory of mind’ skills during an acute episode of psychosis and following recovery , 1998, Psychological Medicine.

[93]  J. Addington,et al.  Facial affect recognition and information processing in schizophrenia and bipolar disorder , 1998, Schizophrenia Research.

[94]  Philip D. Harvey,et al.  Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. , 1998, The American journal of psychiatry.

[95]  R. Heinrichs,et al.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. , 1998, Neuropsychology.

[96]  M. Bell,et al.  Wisconsin Card Sorting Test dimensions in schizophrenia: factorial, predictive, and divergent validity. , 1997, Journal of clinical and experimental neuropsychology.

[97]  A. David,et al.  IQ and risk for schizophrenia: a population-based cohort study , 1997, Psychological Medicine.

[98]  Philip D. Harvey,et al.  Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment , 1997, CNS Spectrums.

[99]  Jane S. Paulsen,et al.  Is it possible to be schizophrenic yet neuropsychologically normal? , 1997, Neuropsychology.

[100]  J. Nadel,et al.  Attribution of mental States to others by schizophrenic patients. , 1997, Cognitive Neuropsychiatry.

[101]  J. Long,et al.  The impact of service characteristics on functional outcomes from community support programs for persons with schizophrenia: a growth curve analysis. , 1997, Journal of Consulting and Clinical Psychology.

[102]  W S Fenton,et al.  Determinants of medication compliance in schizophrenia: empirical and clinical findings. , 1997, Schizophrenia bulletin.

[103]  C. Carter,et al.  Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients , 1996, Biological Psychiatry.

[104]  D. Penn,et al.  The relationship of social cognition to ward behavior in chronic schizophrenia , 1996, Schizophrenia Research.

[105]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[106]  S. Bressi,et al.  Deficit of central executive component of working memory in schizophrenia , 1996 .

[107]  A. Yung,et al.  The prodromal phase of first-episode psychosis: past and current conceptualizations. , 1996, Schizophrenia bulletin.

[108]  S. Sevy,et al.  The cost of cognitive impairment in schizophrenia , 1995, Schizophrenia Research.

[109]  C. Frith,et al.  Schizophrenia, symptomatology and social inference: Investigating “theory of mind” in people with schizophrenia , 1995, Schizophrenia Research.

[110]  M. Bell,et al.  Work Rehabilitation and Improvements in Insight in Schizophrenia , 1995, The Journal of nervous and mental disease.

[111]  Philip D. Harvey,et al.  Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. , 1995, The American journal of psychiatry.

[112]  R. Keefe The contribution of neuropsychology to psychiatry. , 1995, The American journal of psychiatry.

[113]  R. Buchanan,et al.  The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance , 1994, Biological Psychiatry.

[114]  M Marmot,et al.  Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort , 1994, The Lancet.

[115]  M. Tohen,et al.  One hundred years of schizophrenia: a meta-analysis of the outcome literature. , 1994 .

[116]  P. Goldman-Rakic Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[117]  B. Cornblatt,et al.  Impaired attention, genetics, and the pathophysiology of schizophrenia. , 1994, Schizophrenia bulletin.

[118]  M. Strauss,et al.  Relations of symptoms to cognitive deficits in schizophrenia. , 1993, Schizophrenia bulletin.

[119]  A. Baddeley,et al.  Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character , 1992, Psychological Medicine.

[120]  Jean Addington,et al.  Cognitive functioning and positive and negative symptoms in schizophrenia , 1991, Schizophrenia Research.

[121]  R. Gur,et al.  Neuropsychological function in schizophrenia. Selective impairment in memory and learning. , 1991, Archives of general psychiatry.

[122]  K. Mueser,et al.  Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology , 1991, Psychiatry Research.

[123]  S. Marder,et al.  Neuroleptic plasma levels. , 1991, Schizophrenia bulletin.

[124]  R. Liberman,et al.  From noncompliance to collaboration in the treatment of schizophrenia. , 1990, Hospital & community psychiatry.

[125]  J. Ragland,et al.  Neuropsychological assessment of monozygotic twins discordant for schizophrenia. , 1990, Archives of general psychiatry.

[126]  E. Walker,et al.  The positive/negative symptom distinction in schizophrenia validity and etiological relevance , 1988, Schizophrenia Research.

[127]  K. Mueser,et al.  Deficits in facial-affect recognition and schizophrenia. , 1988, Schizophrenia bulletin.

[128]  T. Goldberg,et al.  Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. , 1987, Archives of general psychiatry.

[129]  P S Goldman-Rakic,et al.  Circuitry of the frontal association cortex and its relevance to dementia. , 1987, Archives of gerontology and geriatrics.

[130]  D. Weinberger Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[131]  R. Bilder,et al.  Symptomatic and neuropsychological components of defect states. , 1985, Schizophrenia bulletin.

[132]  R. Heaton,et al.  Use of Neuropsychological tests to predict adult patients' everyday functioning. , 1981, Journal of consulting and clinical psychology.